Sort
82,697 grants matching “vaccine development”
A Nurse-Community Health Worker-Family Partnership Model to Increase COVID-19 Testing in Urban Underserved and Vulnerable Communities
$3,643,065Holly C. Hagan · New York University · P30 · FY2020 · DA
Cellular Immunity to Category A-C Viruses in Humans
$3,639,795Alan L Rothman · Univ Of Massachusetts Med Sch Worcester · U19 · FY2009 · AI
Pre-clinical Vaccine Development for Emerging and Re-emerging Infectious Diseases
$3,639,529John Mascola · National Institute Of Allergy And Infectious Diseases · ZIC · FY2019 · AI
Leadership for HIV/AIDS Clinical Trials Networks; Microbicide Trials Network
$3,637,436Elizabeth Renata Brown · Fred Hutchinson Cancer Research Center · UM1 · FY2012 · AI
Adjuvant Development in the context of vaccines for Zika, Dengue and West Nile virus
$3,635,428Sunil David · Virovax Llc · N01 · FY2020 · AI
NIAID Preclinical Development Support - HIV-1 Envelope Protein Production
$3,629,331Phillip Ishikawa · Advanced Bioscience Laboratories, Inc. · N01 · FY2015 · AI
VACCINE INDUCED IMMUNITY IN THE YOUNG AND AGED
$3,624,942Emory University · U19 · FY2005 · AI
Towards high-resolution structural biology of membrane protein complexes in their native lipid environment
$3,623,275Doreen Matthies · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2023 · HD
Administrative Core
$3,622,426Barton F Haynes · Duke University · U19 · FY2021 · AI
ADVANCING VACCINE ADJUVANT RESEARCH FOR TUBERCULOSIS (AVAR-T)
$3,619,193Warwick Britton · University Of Sydney · N01 · FY2023 · AI
Units for HIV/AIDS Clinical Trials Networks
$3,619,097Ian Matthias Sanne · Wits Health Consortium (Pty), Ltd · UM1 · FY2013 · AI
Harnessing CD4+ T cell responses for long-term protective immunity against HIV
$3,610,004Rafi Ahmed · Scripps Research Institute, The · UM1 · FY2016 · AI
Antigen-specific T-cell Activation, Application to Vaccines for Cancer and AIDS
$3,608,886Jay A Berzofsky · Division Of Clinical Sciences - Nci · ZIA · FY2017 · CA
Advanced Development of Universal Vaccines for Universal Influenza
$3,608,426Christopher Locher · Versatope Therapeutics, Inc. · N01 · FY2024 · AI
Development/production of universal influenza vaccines
$3,607,128Frank Arnold · National Institute Of Allergy And Infectious Diseases · ZIB · FY2017 · AI
A Methamphetamine Conjugate Vaccine: From Manufacturing to IND
$3,606,802Misty Ward Stevens · Intervexion Therapeutics, Llc · U01 · FY2014 · DA
DEVELOPMENT OF A VACCINE CANDIDATE FOR DRUG-RESISTANT FUNGAL INFECTIONS
$3,605,418Gary Nabors · Appili Therapeutics Usa Inc. · N01 · FY2025 · AI
Multicenter AIDS Cohort Study
$3,605,356Steven M Wolinsky · Northwestern University At Chicago · U01 · FY2017 · AI
Center for Human Immunology
$3,604,228James Cherry · National Institute Of Allergy And Infectious Diseases · ZIC · FY2024 · AI
Novel Nanoparticle Platform for the delivery of Vaccines and Adjuvants
$3,603,126Jenny P.y. Ting · Univ Of North Carolina Chapel Hill · U19 · FY2014 · AI
MULTICENTER AIDS COHORT STUDY
$3,601,766John P Phair · Howard Brown Health Center · U01 · FY2008 · AI
Manufacture of SARS-CoV-2 Human Challenge Material
$3,601,220Ray Goodrich · Colorado State University · N01 · FY2020 · AI
EXTRAMURAL RESEARCH FACILITIES IMPROVEMENT PROVEMENT
$3,600,000University Of Maryland Baltimore · C06 · FY2003 · RR
A Genomics Based Investigation of the Determinants of Polymicrobial Infectious Disease Outcomes
$3,600,000David A Rasko · University Of Maryland Baltimore · U19 · FY2020 · AI
A Genomics Based Investigation of the Determinants of Polymicrobial Infectious Disease Outcomes
$3,600,000David A Rasko · University Of Maryland Baltimore · U19 · FY2019 · AI